Qiagen (NYSE:QGEN – Get Free Report)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $43.80, but opened at $42.11. Qiagen shares last traded at $42.14, with a volume of 192,178 shares trading hands.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price target on the stock. in a research note on Thursday, October 17th. UBS Group cut their price target on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research note on Friday. Morgan Stanley reiterated an “equal weight” rating and set a $46.67 price objective (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 price target (up previously from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.84.
Check Out Our Latest Stock Report on QGEN
Qiagen Price Performance
Qiagen (NYSE:QGEN – Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.97% and a net margin of 4.23%. Sell-side analysts expect that Qiagen will post 2.28 earnings per share for the current year.
Hedge Funds Weigh In On Qiagen
Several large investors have recently made changes to their positions in the company. Sequoia Financial Advisors LLC increased its holdings in Qiagen by 7.6% in the fourth quarter. Sequoia Financial Advisors LLC now owns 20,041 shares of the company’s stock valued at $892,000 after buying an additional 1,423 shares in the last quarter. Moors & Cabot Inc. increased its stake in shares of Qiagen by 0.5% in the 4th quarter. Moors & Cabot Inc. now owns 86,474 shares of the company’s stock valued at $3,851,000 after purchasing an additional 426 shares in the last quarter. Johnson Investment Counsel Inc. acquired a new position in Qiagen in the 4th quarter worth about $2,598,000. Barings LLC raised its holdings in Qiagen by 37.5% in the 4th quarter. Barings LLC now owns 414,984 shares of the company’s stock worth $18,490,000 after purchasing an additional 113,270 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in Qiagen by 7.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,498 shares of the company’s stock worth $467,000 after purchasing an additional 742 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.
Qiagen Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Further Reading
- Five stocks we like better than Qiagen
- Do ETFs Pay Dividends? What You Need to Know
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- Expert Stock Trading Psychology Tips
- MarketBeat Week in Review – 02/03 – 02/07
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.